- The stock price of BioCryst Pharmaceuticals (NASDAQ: BCRX) has received a price target of $15 by Piper Sandler. These are the details.
The stock price of BioCryst Pharmaceuticals (NASDAQ: BCRX) has received a price target of $15 by Piper Sandler. And Piper Sandler analyst Tyler Van Buren assigned BioCryst shares an “Overweight” rating.
Piper Sandler analyst Tyler Van Buren wrote that BioCryst had disclosed BCX9930 data that continues to add to the encouraging body of clinical evidence supporting the use in paroxysomal noctural hemoglobinuria. And hemoglobin improvements and the proportion of transfusion-free patients was impressive. While the LDH levels among treatment-naive patients remained at 2 times the ULN after treatment, this is still a marked reduction from the 7.5 times ULN at baseline.
And Van Buren also noted that the ability for BCX9930 to improve the underlying anemia is most clinically meaningful to PNH patients. And it suggests that 9930 could have a place in the PNH treatment paradigm. So Van Buren is looking forward to the initiation of a pivotal trial in PNH during the second half of 2021.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.